ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

lisdexamfetamine

Also written as “SPD489”, “NRP104” and “SPD489 (Lisdexamfetamine dimesylate)”.

Its studies are mostly in Attention Deficit Disorder with Hyperactivity · Schizophrenia · Depressive Disorder, Major · Binge-Eating Disorder · Sleep Deprivation, led by 3 companies.

Drug pageLisdexamfetamine: every studyAll 97 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jul 10, 200747 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takedaits history only450 open or runningphase 4since Jul 10, 2007Oct 31, 2005none ahead
Humanis Saglık Anonim Sirketiits history only10 open or runningphase 1since Jul 25, 2025Jul 25, 2025none ahead
Knoa Pharma10 open or runningphase 3since Aug 28, 2015Aug 28, 2015none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Knoa Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 28, 2015First study: phase 3 study in Attention Deficit Disorder with HyperactivityFirst studyNCT02555150 · 40 enrolled · United States

TargetBeta

“Dopamine transporter releasing agent; Norepinephrine transporter releasing agent; Synaptic vesicular amine transporter inhibitor”ChEMBL 37, by rule

Studies

The one study Knoa Pharma leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02555150Attention Deficit Disorder with Hyperactivity · United States3CompletedJan 201740

How it is read

Names in the registry

  • “SPD489”, 6 entries
  • “NRP104”, 6 entries
  • “SPD489 (Lisdexamfetamine dimesylate)”, 5 entries
  • “Lisdexamfetamine dimesylate”, 5 entries
  • “Lisdexamfetamine Dimesylate”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.